08:23 AM EDT, 09/19/2024 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) shares went up 29% in Thursday's premarket activity after announcing that EDG-7500, an investigational treatment for cardiomyopathy, was found to be well-tolerated in two early trials.

Results showed that EDG-7500 was well-tolerated in both a phase 1 study on healthy subjects and a phase 2 study on patients with obstructive hypertrophic cardiomyopathy, with no significant side effects such as changes in the heart's pumping of blood, Edgewise said.

Edgewise said it began dosing patients for a 28-day part of the obstructive ECM trial and initial results are expected in Q1 next year.

Price: 24.60, Change: +5.53, Percent Change: +28.98